Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia — 20170528

Relapsed/Refractory Acute Myeloid Leukemia (AML) Clinical Trial

Official title:
A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia.

Status Terminated

Clinical Trial Summary

Evaluate the safety and tolerability of AMG 427 in adult subjects with relapsed/refractory AML. Estimate the maximum tolerated dose (MTD) and / or a biologically optimal dose (eg, recommended phase 2 dose [RP2D]).

Clinical Trial Description

Study Design

Related Conditions & MeSH terms

Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Relapsed/Refractory Acute Myeloid Leukemia (AML)

Clinical Trial Details

NCT number	NCT03541369
Study type	Interventional
Source	Amgen
Contact
Status	Terminated
Phase	Phase 1
Start date	September 14, 2018
Completion date	February 28, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05143996` - CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	Phase 1
Completed	`NCT02626338` - Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML	Phase 1/Phase 2
Not yet recruiting	`NCT05662904` - Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients With AML	Phase 1
Recruiting	`NCT06049667` - A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies	Phase 1